Clinical Trial Update: 68Ga-XACP3 PET/CT in Prostate Cancer [NA]

View source ↗

Summary

Clinical trial investigating the PET/CT imaging agent 68Ga-XACP3 for prostate cancer is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Drugs mentioned

• 68Ga-XACP3 (XACP3 radiopharmaceutical)

Snippet

Sponsor: The First Affiliated Hospital of Xiamen University | Conditions: Prostate Cancer, PET/CT | NA | Status: RECRUITING